DHDaisuke Hashimoto

Daisuke Hashimoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daisuke Hashimoto has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pancreatic cancer arising from the remnant pancreas after pancreatectomy: A multicenter retrospective study by the Kyushu study group of clinical cancer

    by Daisuke Hashimoto, Kota Arima, Keisuke Miyake, Atsuko Yonemura, Shigeki Nakagawa, Akira Chikamoto, Hideo Baba

  • Efficacy and safety of postoperative anticoagulation therapy with enoxaparin in patients undergoing pancreatic surgery: a prospective clinical trial

    by Daisuke Hashimoto, Shigeki Nakagawa, Naoki Umezaki, Takanobu Yamao, Yuki Kitano, Kensuke Yamamura, Kota Arima, Takayoshi Kaida, Katsunori Imai, Yo-Ichi Yamashita, et al.

  • Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma

    by Yuki Kitano, Yo-Ichi Yamashita, Kensuke Yamamura, Kota Arima, Takayoshi Kaida, Tatsunori Miyata, Shigeki Nakagawa, Kosuke Mima, Katsunori Imai, Daisuke Hashimoto, et al.

    Background/Aim: As indicators of systemic inflammatory response, the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) predict prognoses for various cancers. This study investigated their prognostic significance in extrahepatic cholangiocarcinoma (ECC). Patients and Methods: We analyzed 120 patients who underwent surgery for ECC between 2000 and 2014. We calculated preoperative NLR and PLR and evaluated their correlations with patients' clinicopathological features and prognosis. Results: Although high NLR was not associated with worse recurrence-free survival (RFS) (hazard ratio (HR)=1.32, p=0.26), cancer-specific survival (CSS) (HR=1.35, p=0.31) and overall survival (OS) (HR=1.19, p=0.52), high PLR was significantly associated with worse RFS (HR=1.85, p=0.01), CSS (HR=2.38, p=0.002) and OS (HR=1.98, p=0.008). In multivariate analysis, high PLR (HR=1.89, p=0.02) and lymph node metastasis (HR=1.78, p=0.03) were independent prognostic factors for OS. A high PLR had more liver recurrences (p=0.04) and recurrences within 1 year (HR=2.38, p=0.02) than low PLR. Conclusion: High preoperative PLR was an independent predictor of poor prognosis for patients with ECC who underwent resections.


  • Open Access

    Surgery for metastatic tumors of the pancreas

    by Taisuke Yagi, Daisuke Hashimoto, Katsunobu Taki, Kensuke Yamamura, Akira Chikamoto, Masaki Ohmuraya, Toru Beppu, Hideo Baba

    Metastatic lesion of the pancreas originated from other organs is uncommon. The aim of this report was to evaluate the outcome of surgery in patients with isolated metastases to the pancreas. Nine patients underwent pancreatic resection for metastatic malignant disease from 2000 to 2015 at the Department of Gastroenterological Surgery of the Kumamoto University Hospital. The primary lesion was renal cell carcinoma in 7 cases, colon cancer in 1 and malignant melanoma in 1. The median interval from the initial operation to pancreatic resection was 138 months. Operative procedure was distal pancreatectomy in 6 cases, pancreaticoduodenectomy in 2 and total pancreatectomy in 1. Two patients with renal cell carcinoma and 1 patient with malignant melanoma died 131, 108, and 4 months after the pancreatic resection, respectively. Other 6 patients have survived until now with 23.5 months of observation periods after pancreatic resection. In conclusion, pancreatic metastasis can develop years after the treatment of primary lesion. Pancreatic resection can achieved long-term survival, at least in the patients who had primary renal carcinoma.


  • Early recurrence and abnormal serum DCP level are poor prognostic factors for HCC patients undergoing radio-frequency ablation therapy on intrahepatic recurrence after curative hepatectomy

    by Hirohisa Okabe, Yo-Ichi Yamashita, Katsunori Imai, Hiromitsu Hayashi, Shigeki Nakagawa, Kota Arima, Daisuke Hashimoto, Akira Chikamoto, Takatoshi Ishiko, Hiroshi Takamori, et al.

    • 1 November 2016
      • Vol. 82  (11) , 1126-1132

    Limited Resection of the Duodenum for Nonampullary Duodenal Tumors, with Review of the Literature.

    by Daisuke Hashimoto, Kota Arima, Akira Chikamoto, Katsunobu Taki, Risa Inoue, Takayoshi Kaida, Takaaki Higashi, Katsunori Imai, Toru Beppu, Hideo Baba

    The surgical management of duodenal pathology is challenging because of its retroperitoneal position and shared blood supply with the pancreas. We present three types of limited resection of the duodenum for the removal of superficial or small nonampullary duodenal (NADL) lesions, and also a review of the English literature regarding management, such as endoscopic resection and limited duodenal resection. Ten cases underwent limited resections of the duodenum for superficial or small NADL lesions from 2011 to 2015. Pancreas-preserving segmental duodenectomy was performed in three cases, local full-thickness resection was performed in three and transduodenal submucosal dissection was performed in four. One patient experienced pancreatic fistula as a postoperative complication. Postoperative pathological diagnosis were adenoma (n = 2), mucosal adenocarcinomas (n = 5), and neuroendocrine tumor (n = 3). Surgical margin was negative in all cases, and no patient has experienced postoperative recurrence or metastasis. Limited resections of the duodenum were feasible and safe procedures for patients with superficial or small NADL lesions. Laparoscopic surgery may be considered in treatment for these tumors. However, the optimal surgical management for superficial or small nonampullary duodenal lesions remains controversial.


  • Open Access

    Co-occurrence of liver metastasis of gastrointestinal stromal tumor and hepatocellular carcinoma: a case report

    by Kohei Yamashita, Yoshifumi Baba, Junji Kurashige, Masaaki Iwatsuki, Katsunori Imai, Daisuke Hashimoto, Yasuo Sakamoto, Akira Chikamoto, Naoya Yoshida, Toru Beppu, et al.

    Gastrointestinal stromal tumors (GISTs) are potentially malignant mesenchymal tumors that can give rise to distant metastases, mainly in the liver. The co-occurrence of synchronous primary liver tumors (e.g., hepatocellular carcinoma (HCC)) in patients with GIST is extremely rare. This report describes a 77-year-old male patient with liver metastasis of GIST originating in the small intestine and synchronous HCC. The patient had undergone resection of the small intestine for the primary GIST 3 years earlier and partial hepatectomy and radiofrequency ablation for liver metastases of GIST 1 year earlier. Despite the continuation of adjuvant therapy with imatinib, two new lesions in the liver were detected by follow-up computed tomography scanning, which showed the gradual enlargement of one tumor. A second hepatectomy was performed. Pathological examination revealed that one tumor was a liver metastasis of GIST and the other was a primary HCC. To our knowledge, this is the first report of the synchronous co-occurrence of a liver metastasis of GIST and a primary HCC.


  • Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma

    by Daisuke Hashimoto, Kota Arima, Naomi Yokoyama, Akira Chikamoto, Katsunobu Taki, Risa Inoue, Takayoshi Kaida, Takaaki Higashi, Hidetoshi Nitta, Masaki Ohmuraya, et al.

    Objectives Activating Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are the most common and frequent changes observed in pancreatic cancer. This study aimed to determine the frequency and extent of intratumoral and metastatic lymph node KRAS mutation heterogeneity of resected pancreatic ductal adenocarcinoma. Methods Tumor tissues macrodissected from tumor centers, invasion fronts (n = 97), and lymph nodes (n = 11) were subjected to DNA extraction and mutation analysis of KRAS codons 12 and 13 by pyrosequencing. Results Activating mutations in codon 12 of KRAS were detected in 90 (92.8%) tumor centers. No mutations were detected in KRAS codon 13 in any patient. After a comparison of tumor centers and invasion fronts, intratumoral heterogeneity of KRAS was observed only in 4 (4.1%) cases. Additional invasion front tumor analysis revealed the same mutation status consistent with each tumor center. No heterogeneity was observed between primary tumors and metastatic lymph nodes. Conclusions Intratumoral heterogeneity of the KRAS mutational status is rare in pancreatic ductal adenocarcinoma. In addition, no KRAS heterogeneity between primary tumors and metastatic lymph nodes was detected in this study. This finding is consistent with the hypothesis that oncogenic activation of KRAS is the first driver mutation in pancreatic cancer.


  • Analysis of hepatic steatosis after surgery for pancreatic carcinoma

    by Akira Chikamoto, Daisuke Hashimoto, Yuki Kitano, Kensuke Yamamura, Kota Arima, Yoshitaka Kaida, Risa Inoue, Takaaki Higashi, Katsunobu Taki, Katsunori Imai, et al.


  • PGE2 signaling promotes the expansion of ALDH1-positive tumor cells in pancreatic ductal adenocarcinoma

    by Kota Arima, Takatsugu Ishimoto, Hirohisa Okabe, Yuki Kitano, Risa Inoue, Kensuke Yamamura, Takayoshi Kaida, Takaaki Higashi, Katsunobu Taki, Katsunori Imai, et al.